Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
2.180
-0.130 (-5.63%)
At close: Jul 18, 2025, 4:00 PM
2.240
+0.060 (2.75%)
After-hours: Jul 18, 2025, 6:56 PM EDT

Company Description

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.

Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018.

Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.

Outlook Therapeutics, Inc.
Outlook Therapeutics logo
CountryUnited States
Founded2010
IPO DateMay 13, 2016
IndustryBiotechnology
SectorHealthcare
Employees23
CEOBob Jahr

Contact Details

Address:
111 S. Wood Avenue, Unit #100
Iselin, New Jersey 08830
United States
Phone609 619 3990
Websiteoutlooktherapeutics.com

Stock Details

Ticker SymbolOTLK
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearOctober - September
Reporting CurrencyUSD
CIK Code0001649989
CUSIP Number69012T206
ISIN NumberUS69012T3059
Employer ID38-3982704
SIC Code2836

Key Executives

NamePosition
Lawrence A. Kenyon CPAEVice President, Chief Financial Officer, Interim Chief Executive Officer, Treasurer, Secretary and Director
Jeffrey EvansonChief Commercial Officer
Joel PrieveSenior Vice President of Licensing and M&A
Dr. Surendra Sharma M.D.Senior Vice President of Medical Affairs
Dr. Jennifer M. Kissner Ph.D.Senior Vice President of Clinical Development and Regulatory Affairs
Jedd ComiskeySenior Vice President - Head of Europe

Latest SEC Filings

DateTypeTitle
Jul 1, 20258-KCurrent Report
Jun 2, 20258-KCurrent Report
May 28, 2025SCHEDULE 13D/AFiling
May 23, 2025424B5Filing
May 23, 20258-KCurrent Report
May 22, 2025424B5Filing
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 15, 20258-KCurrent Report
May 15, 202510-QQuarterly Report